Summary of European Union decisions on marketing authorisations in respect of medicinal products from 6 January 2021 to 6 January 2021

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2021/C 6/11)

— **Issuing of a marketing authorisation** (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
6.1.2021	COVID-19 Vaccine Moderna	COVID-19 mRNA Vaccine (nucleoside modified)	MODERNA BIOTECH SPAIN, S.L. Calle Monte Esquinza 30, 28010 Madrid, España	EU/1/20/1507	dispersion for injection	J07BX	6.1.2021

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
NETHERLANDS

[1] OJ L 136, 30.4.2004, p. 1.